tiprankstipranks
Trending News
More News >

Forte Biosciences Announces Public Offering of Shares

Story Highlights
Forte Biosciences Announces Public Offering of Shares

Don’t Miss TipRanks’ Half-Year Sale

Forte Biosciences ( (FBRX) ) just unveiled an update.

On June 24, 2025, Forte Biosciences announced a public offering of 5,630,450 shares of its common stock at $12.00 per share, along with pre-funded warrants for certain investors. The offering is expected to generate approximately $75 million in gross proceeds, with net proceeds estimated at $70 million, which will be used for working capital and corporate purposes, including clinical and preclinical development. The offering is set to close around June 26, 2025, and aims to support the company’s operations into 2027.

The most recent analyst rating on (FBRX) stock is a Buy with a $68.75 price target. To see the full list of analyst forecasts on Forte Biosciences stock, see the FBRX Stock Forecast page.

Spark’s Take on FBRX Stock

According to Spark, TipRanks’ AI Analyst, FBRX is a Underperform.

Forte Biosciences faces significant challenges with no revenue and increasing operational losses, leading to a weak financial performance. Technical analysis indicates a mixed outlook with bearish long-term trends. The negative P/E ratio and lack of dividend yield highlight valuation concerns. Without positive developments in these areas, the stock remains highly speculative and risky.

To see Spark’s full report on FBRX stock, click here.

More about Forte Biosciences

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune and autoimmune-related diseases, with a key product candidate being FB102, an anti-CD122 monoclonal antibody.

Average Trading Volume: 51,894

Technical Sentiment Signal: Buy

Current Market Cap: $93.29M

Find detailed analytics on FBRX stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1